Stimați colegi,

Vă invităm să participați la Cel de-al XXIII-lea Congres SNPCAR şi a 45-a Conferinţă Naţională de Neurologie-Psihiatrie a Copilului şi Adolescentului şi Profesiuni Asociate din România cu participare internaţională

20-23 septembrie 2023 – IAȘI, Hotel Unirea

Vă așteptăm cu drag!
Prof. Dr. Nussbaum Laura – Președinte SNPCAR

Informații şi înregistrări: vezi primul anunț


Autor: Adrian V. Rus Sheri R. Parris
Distribuie pe:

This review paper examined the following eight neurotransmitters: dopamine, norepinephrine, epinephrine, serotonin, histamine, phenylethylamine (PEA), glutamate, and gamma-aminobutyric acid (GABA).  Specifically, we examined the relationship between these neurotransmitters and psychopathological behaviors that indicate underlying psychological problems or histories of maltreatment. Awareness of these links can provide a deeper understanding of these behaviors as well as assist practitioners in making more informed treatment decisions.


This review paper examined the following eight neurotransmitters: dopamine, norepinephrine, epinephrine, serotonin, histamine, phenylethylamine (PEA), glutamate, and gamma-aminobutyric acid (GABA). The relationship between behavior and these neurotransmitters is discussed below. Some of the neurochemicals listed above are not consistently defined as “neurotransmitters” in the literature due to ambiguity as to whether they affect the central or peripheral nervous system. However, to facilitate reading of this article we will address them all as neurotransmitters.

Neurotransmitters, described as chemical messengers of the nervous system, support the transmission of signals from one neuron to another and ultimately allow the signal to be carried throughout all organs within the body. Neurotransmitters are present in body fluids such as serum, cerebral spinal fluid (CSF), saliva, and urine (Ailts, Ailts, & Bull, 2007). Though present throughout the body, neurotransmitters are primarily synthesized, stored, and released by specialized neurons within the central nervous system (CNS). Most of the essential neurotransmitters are synthesized from amino acids obtained from dietary intake and therefore neurotransmitter precursors may pass through the blood-brain barrier (Ailts, Ailts, & Bull, 2007).


Catecholaminergic neurotransmitters – dopamine, epinephrine and norepinephrine

The major catecholamines in the nervous system are biogenic amines and include dopamine, norepinephrine, and epinephrine (Smeets & González, 2000).  Catecholamines are involved in many behaviors including mood regulation, reward-seeking behavior, and modulation of cardiovascular function, as well as self-regulatory behaviors, cognitive functions, and memory consolidation.  These catecholamines and their relationship with normal and psychopathological behaviors are discussed below.



Dopamine, which has both excitatory and inhibitory effects (Carlson, 2007), is involved in mood regulation and plays a central role in reward-seeking behavior, such as approach, consumption, and addiction; behavioral activation; and goal-directed behavior (Başar & Güntekin, 2008; Pessiglione et al., 2006; Wise, 2004). In particular, dopamine transmission from the sustantia nigra and ventral tegmentum to the forebrain structures such as the nucleus accumbens and neostriatum plays an important role in mediating the reward value of food, drink, sex, social reinforcement, drugs of abuse, and brain stimulation (Berridge & Robinson, 1998). Furthermore, as a principal catecholamine in the mammalian brain, dopamine also aids in the modulation of cardiovascular function, catecholamine release, hormone secretion, vascular tone, renal function, and gastrointestinal motility (Missale, Nash, Robinson, Jaber, & Caron, 1998).

Dopamine is involved also in cognitive functions, in working memory, and intentional and attentional processes (Herschkowitz, 2000). Disturbances in the development of the dopaminergic system may lead to several disorders or abnormalities, including dyskinesia, dystonia, tics, obsessive-compulsive disorders, and abnormal eye movements (Herlenius & Lagererantz, 2001). Dopamine, along with serotonin, GABA, glutamate, opioids, and oxytocin, has also been linked to autism (Penn, 2006). Beard and Conner (2003) suggested that iron deficiency in early life relates to alterations in dopamine metabolism, which may cause problems with perception and motivation; and therefore, problems with cognitive and behavioral development as well. Georgieff (2007) noted that fetal and neonatal iron deficiency can result in low levels of dopamine. Low levels of dopamine have also been correlated with attention problems and ADHD (Volkow et al., 2009; Konrad, Gauggel, & Scurek, 2003). Elevated levels have been linked to cognitive, attention problems (Herschkowitz, 2000), and post-traumatic stress disorder symptoms in adult females (Glover et al., 2003).

Moreover, De Bellis et al. (1999a) found higher levels of urinary dopamine in prepubertal maltreated children with posttraumatic stress disorder (PTSD). Specifically, this study compared 18 maltreated children with PTSD with 24 non-abused children in a control group. Significantly higher levels of catecholamines (including dopamine) were found in the PTSD group than were found in the non-abused control group. In addition, the levels of urinary catecolamines and cortisol correlated positively with intrusive thoughts, avoidance, and hyperarousal.  In another study, De Bellis et al. (1999b) found that 44 maltreated children and adolescents with PTSD who were assessed with anatomical magnetic resonance imaging brain scans had 7% and 8% smaller intracranial and cerebral volume than the control group (61 matched controls on age, gender, handedness, Tanner Stage, race, height, and weight). In addition, the maltreated, PTSD group showed increased rates of internalizing and externalizing disorders consistent with results found in studies of abused children. Overall, these results may be explained, according to the authors of that study, as an effect of chronic maltreatment in children with PTSD that altered major biological stress systems (including catecholaminergic neurotransmitters – dopamine, epinephrine, and norepinephrine), and had adverse effects on brain development.

Furthermore, Yehuda, Southwick, Giller, Ma, and Mason (1992) also found higher levels of dopamine in Vietnam combat veterans with posttraumatic stress disorder (PTSD). In this study, authors explained high levels of dopamine as being a result of increased sympathetic nervous system activation in people with PTSD, and linking severity of PTSD symptom clusters with the level of sympathetic nervous system arousal.



Norepinephrine has both excitatory and inhibitory effects, however, the behavioral effects of norepinephrine are excitatory (Carlson, 2007). The norepinephrine system is dedicated to self-regulatory functions such as mediation of the orienting response, selective attention, and possibly vigilance (Solanto, 1998). Norepinephrine (noradrenaline) is also involved in sleeping, dreaming, and learning; and because it is released in the blood vessels, it causes blood vessels to contract and the heart rate to increase (Başar & Güntekin, 2008). Beane and Marrocco (2004) proposed that insufficient norepinephrine release may explain problems in reflexive and voluntary attention. Viggiano (2008) noted that a decrease in norepinephrine synthesis usually results in hypoactive behavior; however, a chronic increase may result in hypoactivity as well. Norepinephrine is also associated with mood disorders such as manic depression, also known as bipolar disorder (Başar & Güntekin, 2008); arousal modulation; and an organism’s display of sensitivity toward the environment, which may result in aggressive responses to novel or threatening environmental stimuli (Berman & Coccaro, 1998).  Rogeness (1991) found that children with a history of neglect displayed low levels of urinary norepinephrine.

Furthermore, Yehuda, Southwick, Giller, Ma, and Mason (1992) showed higher levels of norepinephrine in Vietnam combat veterans with PTSD than in outpatients and a normal control group. As in the case of significantly higher dopamine levels, high levels of norepinephrine were correlated with increased sympathetic nervous system activation in people with PTSD.

Animal models show that traumatic stress activates the locus coeruleus (the nucleus in the brain that contains catecholamines – specifically norepinephrine) as well as the sympathetic nervous system leading to the “fight-or-flight” response.  Consequently, this influences the increase of catecholamines within the brain, sympathetic nervous system, and adrenal medulla that affect the increase in heart rate, blood pressure, alertness and circulation of epinephrine, norepinephrine, and dopamine. However, during severe stress the locus coeruleus stimulates the hypothalamic-pituitary-adrenal axis (HPA) and corticotropin-releasing hormone (CRH) is released stimulating adrenocorticotropin (ACTH) and cortisol release. This cascade of chemical changes stimulates behavioral activation and intense arousal expressed in anxiety and hypervigilance (De Bellis, 2002)

The norepinephrine balance is affected not just by traumatic stress but also by high levels of chronic physiological stress as shown by Babisch, Fromme, Beyer, and Ising (2001) on noise exposed subjects.  Specifically, they found that traffic volume as an indicator of noise exposure was associated with a higher concentration of noradrenaline in urine.



Epinephrine (adrenaline) is an excitatory neurotransmitter (Feldman, Meyer, & Quenzer, 1997) and is considered to have an effect on human memory consolidation (Cahill, Gorski, & Le, 2003) and stress (Charmandari, Kino, Souvatzoglou, & Chrousos, 2003). Delahanty, Nugent, Christopher, and Walsh (2005) reported that elevated levels of urinary epinephrine were positively correlated to levels of post-traumatic stress disorder in children six weeks after a traumatic event. Krantz, Forsman, and Lundberg (2004) also found that stress increases epinephrine levels. They linked epinephrine to cardiovascular activity and muscle tension. Garde, Hansen, Persson, Ohlsson, and Ørbæk (2003) found that arousal, both positive and negative, was associated with increased concentrations of urinary adrenaline; thus, both positive and negative emotions are associated with increased concentrations of epinephrine. Epinephrine, like dopamine and norepinephrine, has been linked to ADHD as well (Konrad, Gauggel, & Schurek, 2003). Furthermore, Yehuda, Southwick, Giller, Ma, and Mason (1992) showed higher levels of epinephrine in Vietnam combat veterans with PTSD than outpatients and a normal control group.


Catecholamines – Conclusion

Higher levels of epinephrine, norepinephrine, and cortisol in urine may indicate the presence of a state of acute and chronic stress (Babisch, Fromme, Beyer, & Ising, 2001). In addition, animal studies showed altered norepinephrine and epinephrine in plasma as the result of a chronic intermittent stressor (Marby, Gold, & McCarty, 1994).

Norepinephrine and dopamine release in the prefrontal cortex is correlated with a state of arousal (Arnsten & Pliszka, 2011). Under stress conditions, high levels of catecholamines (dopamine and norepinephrine) are released in the prefrontal cortex (Finlay, Zigmond, & Abercrombie, 1995). In addition, low levels of arousal are correlated with low levels of norepinephrine (Foote, Aston-Jones, & Bloom, 1980). The effects of norepinephrine and dopamine on mood, arousal, and behavior are mediated by receptors located within the prefrontal cortex that are sensitive to the neurochemical environment (Arnsten & Pliszka, 2011). Consequently, release of catecholamines that is either insufficient or excessive will lead to impairment of prefrontal cortex function. Specifically, both norepinephrine and dopamine are present in low levels during fatigue and boredom and at moderate levels when an alert state is caused by relevant stimuli or during non-stressed walking. Insufficient levels of dopamine are correlated with unguided attention/responses, distraction, and poor impulse control (untreated ADHD). Moderate norepinephrine levels are correlated with guided attention and responses, and focused, organized and flexible behaviors (optimally treated ADHD). Norepinephrine in high levels is correlated with misguided attention or responses, mental inflexibility or stimulus bond (excessive dose of stimulants) and, impairment of prefrontal cortex functioning (Arnsten & Pliszka, 2011). While the specific cause of ADHD is unidentified, there is evidence that this disorder involves dysfunctional modulation of the cortico-limbic-striatal circuitry by the catecholamines (in particular dopamine, and noradrenaline), as well as serotonin (Dalley, Mar, Economidou, & Robbins, 2008).



Serotonin (5-hydroxytryptamine, 5-HT) has both excitatory and inhibitory effects (Carlson, 2007) and may be involved in a wide variety of behaviors such as appetite; emotion; motor and cognitive functions; modulation of neuroendocrine function; and circadian rhythm (Hensler, 2006). Serotonergic abnormalities have been reported in both autism and epilepsy (Chugani, 2004); depression and anxiety disorders (Ressler & Nemeroff, 2000), and ADHD (Hawi et al., 2002). Other researchers have linked reduced serotonin activity to aggressive behavior toward others, other people’s property, and towards oneself (Meyer et al., 2008; Berman & Coccaro, 1998; Meyer et al., 2008; Mitsis et al., 2000; Oades et al., 2008; Tuinier, Verhoeven, & Van Praag, 1996).  Levels below the optimal range indicate a possibility of depression (Booij, Van der Does, & Riedel, 2003) and poor impulse regulation (Kent et al., 2002). Kaufman et al. (1998) found that childhood abuse can lead to a serotonin system that operates inefficiently, leading to cognitive and behavioral problems. One reason for this may be due to Monoamine oxidase A (MAO-A), an enzyme that catalyzes the degradation of dopamine, serotonin, and norepinephrine. Studies have shown that MAO-A expression is impacted by environmental factors, such as childhood maltreatment (Caspi et al., 2002; Foley et al., 2004; Nilsson, 2006; Nilsson, Sjoberg, Wargelius, & Leppert, 2006). When MAO-A activity is activated by maltreatment, levels of dopamine, serotonin, and norephinephrine are also affected (Oreland, Nilsson, Damberg, & Hallman 2007; Shih & Thompson, 1999).



Histamine has both excitatory and inhibitory effects (Feldman, Meyer, & Quenzer, 1997) and is involved in various central nervous system functions such as arousal, anxiety, activation of the sympathetic nervous system, regulation of sleep-wake cycle, water retention, and suppression of eating (Brown et al., 2001). Some researchers consider histamine to play an important role in regulating energy and endocrine homeostasis, and synaptic plasticity and learning as well (Haas & Panula, 2003). Histamine has also been described as having a modulator role in immune responses (Hough & Leurs, 2006; Tanaka & Ichikawa, 2006).

A high concentration of histamine is found in many foods especially in products of microbiological fermentation such as aged cheese, sauerkraut, wine, processed meat, and citrus foods (Bodmer, Imark & Kneubühl, 1999; Mainz & Novak, 2007; Ruiz-Capillas, & Jiménez-Colmenero, 2004). The amount of histamine found in certain foods may be a contributing factor for high levels of histamine in children. European legislation permits histamine levels twice as high as what the U. S. Food and Drug Administration allows. Some researchers warn against “histamine toxicity” from foods and beverages; thus, there is a need for health authorities to set safe, legal limits on biogenic amines such as histamine (Ruiz-Capillas & Jiménez-Colmenero, 2004).

Allergies, mastocytosis, bacterias, or gastrointestinal bleeding may also cause an excess of histamine (Mainz & Novak, 2007). Mainz and Novak (2007) reported that histamine causes smooth muscle cell contraction, vasodilatation, increased vascular permeability, mucus secretion, tachycardia, alterations of blood pressure, and arrhythmias. The histamine system, proposed as a danger response system, releases more histamine during extreme conditions such as dehydration, hypoglycemia, or stress (Brown, Stevens, & Haas, 2001). In animal studies, histamine has been linked to inducing experimental anxiety, which suggests that histamine may play an important role in the regulation of anxiety (Ikarashi & Yuzurihara, 2002).

Histamine has also been linked to Alzheimer’s disease and schizophrenia (Fernández-Novoa & Cacabelos, 2001) as well as Down’s syndrome and Parkinson’s disease (Haas & Panula, 2003). According to some researchers, histamine also has an effect on memory processes (Blandina, Efoudebe, Cenni, Manaioni, & Passani, 2004; Philippu & Prast, 2001). Histamine has also been associated with anxiety and sleep problems (Brown et al., 2001; Hough & Leurs, 2006; Tanaka & Ichikawa, 2006). Adverse psychological stimulation, such as immobilization stress or social isolation, results in release of Substance P in the brain (Ebner, Rupniak, Saria, & Singewald, 2004). Substance P, a neuropeptide, induces histamine release resulting in inflammation as well as negative moods, fear, and anxiety (Rosenkranz, 2007).



Beta-phenylethylamine (PEA) is an excitatory neurotransmitter that functions like an amphetamine (Kahane, 2009). Decreased PEA levels have been associated with depression (Nakagawara, 1992;) and ADHD (Kusaga et al., 2002). Increased levels have been observed in individuals with anxiety and schizophrenia (see Burchett & Hicks, 2006). There is a very strong association between Monoamine oxidase B (MAO-B), an enzyme that catalyzes the degradation of PEA, and adverse psycho-social environments (e.g., maltreatment) and criminal behavior (Oreland, 2007). In addition, MAO-B is associated with susceptibility to many psychiatric disorders (for a review, see Volavka, 1999), and plays a role in mood regulation (Bortolato, Godar, Davarian, Chen, & Shih, 2009); emotional responses, including exploratory activity, arousal, and behavioral reinforcement (Sabelli & Javaid, 1995); violent criminality (Asberg, 1997; Belfrage, Lindberg, & Oreland, 1992; Longato-Stadler, af Klinteberg, Garpenstrand, Oreland, & Hallman, 2002); and suicide (Verkes et al., 1998). In sum, studies have shown that an individual’s psycho-social environment influences both MAO activity (which has a direct effect on PEA levels) and behavioral expression in individuals.



Glutamate is an excitatory neurotransmitter (Carlson, 2007) and is considered to be the principal mediator of sensory information, motor coordination, emotions, and cognition, including memory formation and memory retrieval (Hassel & Dingledine, 2006). Glutamate also plays a role in alleviating the neuronal effects of stress, anxiety, and modulates neuronal activity throughout the central nervous system (Johnson et al., 2005; Niswender, Jones, & Conn, 2005). It has been implicated in initiation and propagation of seizures (Holmes, 1995) as well as in the pathophysiology of mood disorders (Sanacora, Zarate, Krystal, & Manji, 2008). Glutamate has also been implicated in depersonalization disorder, which has been associated with childhood emotional maltreatment and trauma (Simeon, 2004). Furthermore, an excess of glutamate has been associated with obsessive-compulsive disorder (Carlsson, 2000), while a shortage has been associated with ADHD (Moore et al., 2006) and depressive symptoms (Tordera et al., 2011). Glutamate dysfunction has also been associated with autism (Page et al., 2006; Shinohe et al., 2006) and schizophrenia (Coyle, 2006). Acute stress alters the release of glutamate in the brain (Musazzi et al., 2010) and rearing environments marked by neglect and isolation are associated with reduced expression of glutamate in the brain, leading to cognitive deficits and psychiatric disorders. Glutamate dysfunction caused by stress is also suspected to play a role in schizophrenia and addiction (Melendez, Gregory, Bardo, & Kalivas, 2004). Extremely high glutamate levels, which lead to cell damage/death, have been found in children with traumatic brain injury who have also been victims of child abuse (Ruppel, 2001).



Gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the CNS, plays a trophic role during early brain development, including neuronal wiring, plasticity of neuronal network, and neural organization (Herlenius & Lagercrantz, 2001). GABA synthesis reaches peak activity during the second year of life; thus, at age two, children should show improvement in integrating information (Herschkowitz, 2000). Olsen and Betz (2006) reported a link between altered GABAergic function and neurological and psychiatric disorders, primarily related to hyperexcitability, including developmental malfunctions; mental retardation and epilepsy, sleep disorders; drug dependence, sensorimotor processing, and motor coordination. Brambila, Perez, Barale, Schettini, and Soares (2003) reported low levels in both depressed and manic patients. Johnston and Singer (2001) reported low levels of GABA in cerebral spinal fluid in individuals with seizures. Moreover, elevated plasma GABA levels have been found in youngsters with Autistic Disorder, and some researchers consider GABA to be a biochemical marker of Autism (Dhossche et al., 2002) as well of ADHD with conduct disorder (Prosser et al., 1997).



In summary, maltreatment can affect levels of the neurotransmitters discussed above.  Health and childcare practitioners should be aware that children with histories of trauma, neglect, and other forms of maltreatment often exhibit behavior that is driven by irregular levels of neurotransmitters that stem from maltreatment (Purvis, McKenzie, Cross, Kellermann, & Huisman, 2011). Urinary assays to assess specific levels of each neurotransmitter to determine whether they are within optimal ranges may be helpful in planning appropriate therapies and interventions (e.g., behavioral or psychological interventions, supplements, or medication) and also in assessing the efficacy of interventions.

In a recent study, significant reduction in maladaptive behaviors was observed for at-risk children when serotonin and Gaba were increased with natural supplements (Cross, Kellermann, McKenzie, Purvis, Hill, & Huisman, 2011). Furthermore, NT testing has been used to detect child abuse. In one case study, a mother was seeking reinstatement of full custody of her child who had been in foster care for one year. However, the child demonstrated extreme reactions to her mother’s presence during visitation sessions. The child was tested for neurotransmitter activity at baseline and immediately after visitation by the mother. A spike in the levels of several neurotransmitters after visitation indicated a dramatic stress response associated with the visitation. When the mother was presented with these neurotransmitter results as well as her results on the Adult Attachment Interview (AAI), she confessed to using abusive parenting practices with the child (Purvis, McKenzie, Kellermann, & Cross, 2010).




  1. Ailts, J., Ailts, D., & Bull, D. (2007). Urinary Neurotransmitter Testing: Myths and  Misconceptions. Retrieved January 20, 2013, from
  2. Arnsten, A. F. T., & Pliszka, S. R. (2011). Catecholamine influences on prefrontal cortical  function: Relevance to treatment of attention deficit/hyperactivity disorder and related disorders. Pharmacology, Biochemistry and Behavior, 99(2), 211-216.
  3. Asberg, M. (1997). Neurotransmitters and suicidal behavior: The evidence from  cerebrospinal fluid studies. Annals of the New York Academy of Sciences, 836, 158- 181.
  4. Babisch, W., Fromme, H., Beyer, A., & Ising (2001). Increased catecholamine levels in urine  in subjects exposed to road traffic noise: The role of stress hormones in noise  research. Environment International, 26, 475-481.
  5. Başar, E., & Güntekin, B. (2008). A review of brain oscillations in cognitive disorders and the role of neurotransmitters.  Brain Research, 1235, 172-193.
  6. Beane, M., & Marrocco, R. T. (2004). Norepinephrine and acetylcholine mediation of the  components of reflexive attention: implications for attention deficit disorders.  Progress in Neurobiology, 74, 167-181.
  7. Beard, J. L., & Connor, J. R. (2003). Iron status and neural functioning. Annual Review of  Nutrition, 23, 41-58.
  8. Belfrage, H., Lidberg, L., & Oreland, L. (1992). Platelet monoamine oxidase activity in  mentally disordered violent offenders. Acta Psychiatrica Scandinavica, 85, 218-221.
  9. Berman, M. E., & Coccaro, E. F. (1998). Neurobiologic Correlates of Violence: Relevance to  Criminal Responsibility. Behavioral Sciences and the Law, 16, 303-318.
  10. Berridge, K. C., & Robinson, T. E. (1998). What is the role of dopamine in reward: hedonic  impact, reward learning, or incentive salience? Brain Research Review, 28, 309-369.
  11. Blandina, P., Efoudebe, M., Cenni, G., Mannaioni, P., & Passani, M. B. (2004). Acetylcholine, Histamine, and Cognition: The Sides of the Same Coin. Learning & Memory, 11, 1-8.
  12. Bodmer, S., Imark, C., & Kneubühl, M. (1999). Biogenic amines in foods: Histamine and  food processing. Inflammation Research, 48, 296-300.
  13. Booij, L., Van der Does, A. J. W., & Riedel, W. J. (2003). Monoamine depletion in  psychiatry and healthy population: Review. Molecular Psychiatry, 8, 951-973.
  14. Bortolato, M., Godar, S. C., Davarian, S., Chen, K., & Shih, J. (2009). Behavioral  disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient  mice. Neuropsychopharmacology, 34, 2746-2757.
  15. Brambila, P., Perez, J., Barale, F., Schettini, G., & Soares, J. C. (2003). GABAergic  dysfunction in mood disorders. Molecular Psychiatry, 8, 721–737.
  16. Brown, R. E., Stevens, D.R., & Haas, H. L. (2001). The physiology of brain histamine.  Progress in Neurobiology, 63(6), 637-72.
  17. Burchett, S. A., & Hicks, T. P. (2006). The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain. Progress in Neurobiology, 79(5-6), 223-246.
  18. Cahill, L., Gorski, L., & Le, K. (2003). Enhanced Human Memory Consolidation with Post- Learning Stress: Interaction with the Degree of Arousal at Encoding. Learning &  Memory, 10(4), 270-274.
  19. Carlson, N. R. (2007). Physiology of behavior, 9th ed. Boston, MA: Pearson.
  20. Carlsson, M. L. (2000). On the role of cortical glutamate in obsessive-compulsive disorder  and attention-deficit hyperactivity disorder, two phenomenologically antithetical  conditions. Acta Psychiatr Scand, 102, 401-413.
  21. Caspi, A., McClay, J., Moffitt, T. E., Mill, J., Martin, J., Craig, I. W., Taylor, A., & Poulton,  R. (2002). Role of genotype in the cycle of violence in maltreated children.  Science,  297, 851-854.
  22. Cross, D. R., Kellermann, G., Mckenzie, L. B., Purvis, K. B., Hill, G. J., & Huisman, H. (2010). A randomized targeted amino acid therapy with behaviourally at-risk adopted children. Child: Care, Health and Development. 37(5), 671-678.
  23. Charmandari, E., Kino, T., Souvatzoglou, E., & Chrousos, G. P. (2003). Pediatric Stress: Hormonal Mediators and Human Development. Hormone Research, 59, 161-179.
  24. Chugani, D. C. (2004). Serotonin in autism and pediatric epilepsies. Mental Retardation and Developmental Disabilities Research Reviews, 10, 112-116.
  25. Coyle, J. T. (2006). Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cellular and Molecular Neurobiology, 26(4-6), 365-384.
  26. Dalley, J. W., Mar, A. C., Economidou, D., & Robbins, T. W. (2008). Neurobehavioral  mechanisms of impulsivity: Fronto-striatal systems and functional neurochemistry. Pharmacology, Biochemistry and Behavior 90, 250–260.
  27. De Bellis, M. D. (2002). Developmental traumatology: a contributory mechanism for alcohol  and substance use disorders. Psychoneuroendocrinology, 27, 155-170.
  28. De Bellis, M. D., Baum, A. S., Birmaher, B.,  Keshavan, M. S., Eccard, C. H., Boring, A. M., et al. (1999a). Developmental traumatology. Part I: Biological stress systems.  Biological Psychiatry, 45(10), 1259-1270.
  29. DeBellis, M.D., Keshavan, M.S., Clark, D.B., Casey, B.J., Giedd, J.N., Boring, A.M., et al.  (1999b). Developmental traumatology. Part II: Brain development. Biological Psychiatry, 45(10), 1271-1284.
  30. Dhossche, D., Applegate, H., Abraham, A., Maertens, P., Bland, L., Bencsath, A., &  Martinez, J. (2002). Elevated plasma gamma-aminobutyric acid (GABA) levels in  autistic youngster: stimulus for a GABA hypothesis of autism. Medical Science  Monitor, 8(8), 1-6.
  31. Delahanty, D. L., Nugent, N. R., Christopher, N. C., & Walsh, M. (2005). Initial urinary  epinephrine and cortisol levels predict acute PTSD symptoms in child trauma victims.  Psychoneuroendocrinology, 30, 121-128.
  32. Ebner, K., Rupniak, N. M., Saria, A., & Singewald, N. (2004). Substance P in the medial amygdala: Emotional stress-sensitive release and modulation of anxiety-related  behavior in rats. Proceedings of the National Academy of Sciences of the United  States of America, 101(12), 4280-4285.
  33. Feldman, R. S., Meyer, J. S., & Quenzer, L. F. (1997). Principles of  neuropsychopharmacology. Sunderland, Massachusetts: Sinauer Associates, Inc.
  34. Fernández-Novoa, L., & Cacabelos, R. (2001). Histamine function in brain disorder.  Behavioural Brain Research, 124, 213-233.
  35. Finlay, J. M., Zigmond, M. J., & Abercrombie, E. D. (1995). Increased dopamine and  norepinephrine release in medial prefrontal cortex induced by acute and chronic  stress: effects of diazepam. Neuroscience, 64, 619–28.
  36. Foley, D. L., Eaves, L. J., Wormley, B., Silberg, J. L., Maes, H. H., Kuhn, J., & Riley, B.  (2004). Childhood adversity, monoamine oxidase A genotype, and risk for conduct  disorder. Archives of General Psychiatry, 61, 738-744.
  37. Foote, S.L., Aston-Jones, G., & Bloom, F. E. (1980). Impulse activity of locus coeruleus  neurons in awake rats and monkeys is a function of sensory stimulation and arousal.  Proc. Natl. Acad. Science. USA, 77(5), 3033-3037.
  38. Garde, A. H., Hansen, Å. M., Persson, R.; Ohlsson, K., & Ørbæk, P. (2003). The influence of production systems on physiological responses measured in urine and saliva. Stress  and Health: Journal of the International Society for the Investigation of Stress, 19(5),  297-306.
  39. Georgieff, M. K. (2007). Nutrition and the developing brain: nutrient priorities and  measurement. American Journal of Clinical Nutrition, 85, 614S-620S.
  40. Glover, D. A., Powers, M. B., Bergman, L., Smith, J. A. J., Telch, M. J., & Stuber, M.  (2003). Urinary dopamine and turn bias in traumatized women with and without  PTSD symptoms. Behavioural Brain Research, 144, 137–141.
  41. Haas, H., & Panula, P. (2003). The role of histamine and the tuberomamillary nucleus in the nervous system. Nature Reviews. Neuroscience, 4(2), 121-130.
  42. Hassel, B., & Dingledine, R. (2006). Glutamate. In Siegel, G. J., Albers, R. W., Brady, S. T.,  & Price, D. L. (Eds.), Basic Neurochemistry: Molecular, Cellular, and Medical Aspects (267-290). San Diego, Ca:  Elsevier Academic Press.
  43. Hawi, Z., Dring, M., Kirley, A., Foley, D., Kent, L., & Craddock, N. (2002). Serotonergic  system and attention deficit hyperactivity disorder (ADHD): A potential susceptibility  locus at the 5-HT1B receptor gene in 273 nuclear families from a multi-centre sample.  Molecular Psychiatry, 7, 718-725.
  44. Hensler, J. G. (2006). Serotonin. In G. J. Siegel, R. W. Albers, S. T. Brady, & D. L. Price (Eds.), Basic Neurochemistry: Molecular, Cellular, and Medical Aspects (227-248).  San Diego, Ca: Elsevier Academic Press.
  45. Herlenius, E., & Lagererantz, H. (2001). Neurotransmitters and neuromodulators during early  human development. Early Human Development, 65(1), 21-37.
  46. Herschkowitz, N. (2000). Neurological bases of behavioral development in infancy. Brain &  Development, 22, 411-416.
  47. Holmes, G. L. (1995). Role of glutamate and GABA in the pathophysiology of epilepsy.  Mental Retardation and Developmental Disabilities Research Review, 1, 208-219.
  48. Hough, L. B., & Leurs, R. (2006). Histamine. In G. J. Siegel, R. W. Albers, S. T. Brady, & D. L. Price (Eds.), Basic Neurochemistry: Molecular, Cellular, and Medical Aspects (249-265). San Diego, Ca:  Elsevier Academic Press.
  49. Ikarashi Y., & Yuzurihara, M. (2002). Experimental anxiety induced by histaminergics in  mast cell-deficient and congenitally normal mice. Pharmacology, Biochemistry, &  Behavior, 72(1-2), 437-441.
  50. Johnson, M. P., Barda, D., Britton, T. C., Emkey, R., Hornback, W. J., Jagdmann, G. E.,
  51. McKinzie, D. L., et al. (2005). Metabotropic glutamate 2 receptor potentiators:  Receptor modulation, frequency-dependent synaptic activity, and efficacy in  preclinical anxiety and psychosis model(s). Psychopharmacology, 179, 271-283.
  52. Johnston, M. V., & Singer, H. S. (2001). Brain Neurotransmitter and Neuromodulators in  Pediatrics. Pediatrics, 70(1), 57-68.
  53. Kahane, A. (2009). Urinary neurotransmitter analysis as a biomarker for psychiatric disorders. Townsend Newsletter, 306, 70.
  54. Kaufman, J., Birmaher, B., Perel, J., Dahl, R. E., Stull, S., Brent, D., et al. (1998).  Serotonergic functioning in depressed abused children: Clinical and familial  correlates. Biological Psychiatry, 44, 973-981.
  55. Kent, L., Doerry, U., Hardy, E., Parmar, R., Gingell, K., Hawi, Z., et al. (2002). Evidence that  variation at the serotonin transporter gene influences susceptibility to attention deficit  hyperactive disorder (ADHD): Analysis and pooled analysis. Molecular Psychiatry, 7,  908-912.
  56. Konrad, K., Gauggel, S., & Scurek, J. (2003). Catecholamine functioning in children with  traumatic brain injuries and children with attention-deficit / hyperactivity disorder.  Cognitive Brain Research, 16, 425–433.
  57. Krantz, G., Forsman, M., & Lundberg, U. (2004). Consistency in physiological stress  responses and electromyographic activity during induced stress exposure in  women and men. Integrative Physiological & Behavioral Science, 39(2), 105-118.
  58. Kusaga, A., Yamashita, Y., Koeda, T., Hiratani, M., Kaneko, M., Yamada, S., & Matsuishi, T. (2002). Increased Urine Phenylethylamine after Methylphenidate Treatment in Children with ADHD. Annals of Neurology, 52(3), 371-374.
  59. Longato-Stadler, E., af Klinteberg, B., Garpenstrand, H., Oreland, L., & Hallman, J. (2002). Personality traits and platelet MAO activity in a Swedish male criminal population.  Neuropsychobiology, 46, 202-208.
  60. Mainz, L., & Novak, N. (2007). Histamine and histamine intolerance. The American Journal  of Clinical Nutrition, 85, 1185-1196.
  61. Marby, T. R., Gold, P. E., & McCarty, R. (1994). Age related changes in plasma catecholamine responses to chronic intermittent stress. Physiology & Behavior, 58(1),  49-56.
  62. Melendez, R. I., Gregory, M. L., Bardo, M. T., & Kalivas, P. W. (2004). Impoverished  rearing environment alters metabotropic glutamate receptor expression and function  in the prefrontal cortex. Neuropsychopharmacology, 29, 1980-1987.
  63. Meyer, J. H., Wilson, A. A., Rusjan, P., Clark, M., Houle, S., & Woodside, S., et al. (2008).  Serotonin2A receptor binding potential in people with aggressive and violent behavior.  Journal of Psychiatry and Neuroscience, 33(6), 499-508.
  64. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., & Caron, M. G. (1998). Dopamine  Receptors: From Structure to Function. Psychological Review, 78(1), 198-225.
  65. Mitsis, E. M., Halperin, J. M., & Newcorn, J. H. (2000). Serotonin and Aggression in  Children. Current Psychiatry Reports, 2, 95-101.
  66. Moore, C. M., Biederman, J., Wozniak, J., Mick, E., Aleardi, M., Wardrop, M., et al. (2006).  Differences in Brain Chemistry in Children and Adolescents With Attention Deficit  Hyperactivity Disorder With and Without Comorbid Bipolar Disorder: A Proton Magnetic Resonance Spectroscopy Study. The American Journal of Psychiatry, 163,  316-318.
  67. Musazzi, L., Milanese, M., Farisello, P., Zappettini, S., Tardito, D., Barbiero, V. S., et al.  (2010). Acute stress increases depolarization-evoked glutamate release in the rat  prefrontal/frontal cortex: The dampening action of antidepressants. European  Neuropsychopharmacology, 20, S27-S28.
  68. Nakagawara, M. (1992). Beta-phenylethylamine and noradrenergic function in depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 16, 45-53.
  69. Nilsson, K. W. (2006). Gene-environment interaction in adolescent deviant behavior.  Uppsala University, Uppsala.
  70. Nilsson, K. W., Sjoberg, R. L., Wargelius, H., Leppert, J., Lindstrom, L., & Oreland, L.  (2006). The monoamine oxidase A (MAO-A) gene, family function and maltreatment as predictors of destructive behavior during male adolescent alcohol  consumption, Addiction, 102, 389-398.
  71. Niswender, C. M., Jones, C. K., & Conn, P. J. (2005). New therapeutic frontiers for  metatropic glutamate receptors. Current Topics in Medicinal Chemistry, 5, 847-857.
  72. Oades, R. D., Lasky-Su, Christiansen, H., Faraone, S. V., Sonuga-Barke, E. J. S., & Banaschewski, T., et al. (2008). The influence of serotonin- and other genes on  impulsive behavioral aggression and cognitive impulsivity in children with attention- deficit/hyperactivity disorder (ADHD): Findings from a family-based association test  (FBAT) analysis. Behavioral and Brain Functions, 4:48.
  73. Olsen, R. W., & Betz, H. (2006). GABA and Glycine. In G. J. Siegel, R. W. Albers, S. T. Brady, & D. L. Price (Eds.), Basic Neurochemistry: Molecular, Cellular, and Medical  Aspects (291-301). San Diego, Ca: Elsevier Academic Press.
  74. Oreland, L., Nilsson, K., Damberg, M., & Hallman, J. (2007). Monoamine oxidases – activities, genotypes and the shaping of behavior. Journal of Neural Transmission,  114, 817-822.
  75. Page, L. A., Daly, E., Schmitz, N., Simmons, A., Toal, F., et al. (2006). In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in  autism. American Journal of  Psychiatry, 163, 2189-2192.
  76. Penn, H. E. (2006). Neurobiological Correlates of Autism: A Review of Recent Research.  Child Neuropsychology, 12, 57–79.
  77. Pessiglione, M., Seymour, B., Flandin, G., Dolan, R. J., & Frith, C. D. (2006). Dopamine- dependent prediction errors underpin reward-seeking behaviour in humans. Nature, 442, 1042-1045.
  78. Philippu, A., & Prast, H. (2001). Importance of histamine in modulatory process, locomotion  and memory. Behavioural Brain Research, 124, 151-159.
  79. Prosser, J., Hughes, C. W., Sheikha, S., Kowatch, R. A., Kramer, G. L., Rosenbarger, N., et al. (1997). Plasma GABA in children and adolescents with mood, behavior, and  comorbid mood and behavior disorders: A preliminary study. Journal of Child and  Adolescent Psychopharmacology, 7(3), 181-199.
  80. Purvis, K. B., McKenzie, L. B., Cross, D. R., Kellermann, G., & Huisman, H. (2011). A randomized targeted amino acid therapy with behaviourally at-risk adopted children. Child: Care, Health, and Development, 37(5), 671-678.
  81. Purvis, K. B., McKenzie, L. B., Kellermann, G., & Cross, D. R. (2010). An attachment based approach to child custody evaluation: A case study. Journal of Child Custody, 7, 45- 60.
  82. Ressler, K. J., & Nemeroff, C. B. (2000). Role of serotonergic and noradrenergic systems in  the pathophysiology of depression and anxiety disorders. Depression and Anxiety,  12(1), 2-19.
  83. Rogeness, G. A. (1991). Psychosocial factors and amine systems. Psychiatry Research, 37(2),  215-217.
  84. Rosenkranz, M. A. (2007). Substance P at the nexus of mind and body in chronic inflammation and affective disorders, Psychological Bulletin, 133(6), 1007-1037.
  85. Ruiz-Capillas, C., & Jiménez-Colmenero, F. (2004). Biogenic Amines in Meat and Meat  Products. Clinical Reviews in Food Science and Nutrition, 44, 489-499.
  86. Ruppel, R. A., Kochanek, P. M., Adelson, P. D., Rose, M. E., Wisniewski, S. R., Bell, M. J., Clark, R. S., Marion, D. W., & Graham, S. H. (2001). Excitatory amino acid  concentrations in ventricular cerebrospinal fluid after severe traumatic brain injury in infants and children: The role of child abuse. The Journal of Pediatrics, 138(1), 18- 25.
  87. Sabelli, H. C., & Javaid, J. I. (1995). Phenylethylamine modulation of affect: Therapeutic and diagnostic implications. Journal of Neuropsychiatry and Clinical Neurosciences, 7, 6- 14.
  88. Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008). Targeting the  glutamatergic system to develop novel, improved therapeutics for mood disorders.  Nature Review, 7, 426-437.
  89. Shih, J. C., & Thompson, R. F. (1999). Monoamine oxidase in neuropsychiatry and behavior.  American Journal of Human Genetics, 65, 593-598.
  90. Shinohe, A., Hashimoto, K., Nakamura, K., Tsujii, M., Iwata, Y., et al. (2006). Increased  serum levels of glutamate in adult persons with autism. Progress in Neuro- Psychopharmacology & Biological Psychiatry, 30, 1472-1477.
  91. Simeon, D. (2004). Depersonalisation disorder: A contemporary overview. CNS Drugs,  18(6), 343-354.
  92. Smeets, W. J. A. J., & González, A. (2000). Catecholamine system in the brain of vertebrates:  New perspectives through a comparative approach. Brain Research Reviews, 33, 308- 379.
  93. Solanto, M. V. (1998). Neuropsychopharmacological mechanisms of stimulant drug action in  attention-deficit hyperactivity disorder: A review and integration. Behavioural Brain  Research, 94, 127–152.
  94. Tanaka, S., & Ichikawa, A. (2006). Recent advances in molecular pharmacology of the  histamine systems: Immune regulatory role of histamine produced by leukocytes.  Journal of Pharmacological Sciences, 101(1), 19-23.
  95. Tordera, R. M., Garcia-Garcia, A. L., Elizade, N., Segura, V., Aso, E., Venzala, E., et al.  (2011). Chronic stress and impaired glutamate function elicit a depressive-like  phenotype and common changes in gene expression in the mouse frontal cortex.  European Neuropsychopharmacology, 21(1), 23-32.
  96. Tuinier, S., Verhoeven, W. M. A., & Van Praag, H. M. (1996). Serotonin and disruptive  behavior: A critical evaluation of the clinical data. Human Psychopharmacology, 11, 469-482.
  97. Verkes, R. J., Van der Mast, R. C., Kerkhof, A. J., Fekkes, D., Hengeveld, M. W., Tuyl, J. P.,  et al. (1998). Platelet serotonin, monoamine oxidase activity, and [3H]paroxetine  binding related to impulsive suicide attempts and borderline personality disorder.  Biological Psychiatry, 43, 740-746.
  98. Viggiano, D. (2008). The hyperactive syndrome: Metanalysis of genetic alterations,  pharmacological treatments and brain lesions which increase locomotor activity.  Behavioural Brain Research, 194, 1–14.
  99. Volavka, J. (1999). The neurobiology of violence: An update. Journal of Neuropsychiatry &  Clinical Neurosciences, 11, 307-314.
  100. Volkow, N. D., Wang G. J., Kollins, S. H., Wigal, T. L., Newcorn, J. H., Telang, F., et al.  (2009). Evaluating dopamine reward pathway in ADHD: Clinical implications.  JAMA, 302(10), 1084-1420.
  101. Wise, R. A. (2004). Dopamine, learning and motivation. Nature Reviews Neuroscience, 5, 1- 12.
  102. Yehuda, R., Southwick, S. M., Giller, E. L., Ma, X., & Mason, J. W. (1992). Urinary  catecholamine excretion and severity of PTSD symptoms in Vietnam combat  veterans. Journal of Nervous and Mental Disease, 180(5), 321-325.

Correspondence to: |